Genetic markers of risk for ST-elevated myocardial infarction

Aim. To identify genetic markers of risk for ST-elevated myocardial infarction (STEMI).

Material and methods. The study included 210 patients (119 men, 91 women) with STEMI, hospitalized from December 21, 2016 to June 16, 2017 The average age of men was 55,5±9,5 years, women — 57,5±9,1 years. The diagnosis of STEMI was verified according to the criteria of the European Society of Cardiology (2015, 2017). During hospitalization, patients underwent clinical and instrumental examination, stipulated by medical care standards and clinical guidelines We also conducted a genetic study of single nucleotide polymorphisms (SNPs), which showed their association with the risk of coronary artery disease (CAD) and acute myocardial infarction (AMI) according to the GWAS: rs2820315 of the LMOD1 gene (Leiomodin 1, mapped on chromosome 1), rs9349379 of the PHACTR1 gene (regulator 1 of actin and phosphotase, localized on chromosome 6p241), rs867186 of the PROCR gene (Protein C receptor, located on chromosome 20q11.22), rsi1799883 of the FABP2 gene (Fatty acid-binding protein 2, located on chromosome 4q26). Statistical data analysis was performed using the SPSS 170.5 software package and authorial odds ratio (OR) calculator.

Results. Carriage of the CC genotype of rs2820315 polymorphism of the LMOD gene is associated with an increased risk of STEMI by 1,87 times (95% CI 1,2862,722, p=0,016). Carriers of the CT genotype of rs2820315 polymorphism have a reduced risk of STEMI (OR 0,633; 95% CI 0,436-0,918, p=0,016).

Conclusion. In order to identify risk groups for STEMI development, the study of the rs2820315 polymorphism of the LMOD gene is recommended. This will define the high-risk group for STEMI for developing of personalized programs for primary and secondary prevention of cardiovascular events in practical health care, which will contribute to reducing of STEMI mortality.

1. Boytsov SA, Samorodskaja IV, Nikulina NN, et al. Comparative analysis of mortality from acute forms of coronary heart disease for the fifteen-year period in the Russian Federation and the USA and the factors affecting its formation. Terapevticheskij arhiv. 2017;89(9):53-9. (In Russ.) doi:1017116/terarkh201789953-59.

2. Boytsov SA, Provatorov SI. Cardiovascular diseases in the Russian Federation: the main components of mortality and prevention. Vestnik Roszdravnadzora. 2018;5:12-8. (In Russ.)

3. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;23(6):7-122. (In Russ.) doi:10.15829/1560-4071-2018-6-7-122.

4. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Russ J Cardiol. 2017;22(6):7-85. (In Russ.)

5. Roffi M, Patrono C., Collet JP. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315. doi:10.1093/eurheartj/ehv320. Epub 2015 Aug 29.

6. Puymirat E, Simon T, Cayla G, et al. Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015. Circulation. 2017;136:1908-19. doi: 10.1161/circulationaha.117.030798.

7. Maksimov VN, Orlov PS, Ivanova АА, et al. Complex evaluation of the significance of populational genetic markers associated With myocardial infarction and risk factors. Russ J Cardiol. 2017;22(10):33-41. (In Russ.) doi:10.15829/15604071-2017-10-33-41.

8. Howson JM, Zhao W, Barnes DR, et al. Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms. Nat Genet. 2017;49:1113-9. doi:10.1038/ng.3874.

9. Lozhkina NG, Khasanova MH, Kuimov AD, et al. Multifactorial Prognostication of Remote Outcomes in Patients With Non-ST Elevation Acute Coronary Syndrome. Kardiologiia. 2017;57(8):28-33. (In Russ.) doi 10.18087/cardio.2017.8.10014.

10. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(38):119-77. doi:10.1093/eurheartj/ehx393.

11. Chen L, Qian H, Luo Z. PHACTR1 gene polymorphism with the risk of coronary artery disease in Chinese Han population. Postgrad Med J. 2019;95:67-71 doi: 10.1136/postgradmedj-2018-136298.

12. Gonzalez-Becerra K, Ramos-Lopez O, Garcia-Cazarin ML, et al. Associations of the lipid genetic variants Thr54 (FABP2) and -493T (MTTP) with total cholesterol and low-density lipoprotein cholesterol levels in Mexican subjects. J Int Med Res. 2018;46(4):1467-76. doi:10.1177/0300060517748518.